NCT07004010View on ClinicalTrials.gov

Evaluating the Efficacy and Safety of Embella (Deoxycholic Acid, Produced by Espad Pharmed Co.) for the Treatment of Flank Fat

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2024

Conditions
Flank Fat
Interventions
DEVICE

Deoxycholic Acid Injection

The intervention include Deoxycholic acid, SC, 0.15 ml each injection, up to 2-4 ml in each site (2 ml at visit 1 for everyone, and 2 ml at visit 2 unless the patient does not agree)

Trial Locations (1)

19947-66411

Orchid Pharmed, Medical Department, Tehran

All Listed Sponsors
lead

Espad Pharmed

INDUSTRY

NCT07004010 - Evaluating the Efficacy and Safety of Embella (Deoxycholic Acid, Produced by Espad Pharmed Co.) for the Treatment of Flank Fat | Biotech Hunter | Biotech Hunter